Amorfix detects vCJD prions in blood from non-human primates
Amorfix Life Sciences announced it has detected prions in blood from non-human primates that were orally-infected with BSE and developed a primate version of vCJD.
"Amorfix was able to obtain only a limited number of these very rare primate samples. Considering the small number of samples tested, these results are promising," said Dr. Neil Cashman, Chief Scientific Officer of Amorfix. "Given these results and the similarity of this primate model to humans, it is important to now test human vCJD blood samples."
Blood samples were obtained from a European-sponsored vCJD primate study. Amorfix previously reported detecting endogenous prions in blood from sheep with prion disease (scrapie), but biochemical detection of vCJD endogenous prions in cynomolgus primates has never before been reported. It is known that the blood from primates with vCJD is infectious as transfusion of the blood resulted in transmission of the disease. The Company made minor modifications to its EP-vCJD™ blood screening assay in order to test the primate samples.
The results of the study demonstrated a trend in the measure of prion detection. The highest signals were detected in blood from two non-human primates, one of which was clinically symptomatic and one which was presymptomatic. Blood samples from two other pre-symptomatic animals were found to have intermediate results. Each sample was tested on two separate days in blinded panels that included control plasma samples. These rare primate samples were the only ones available at this time from the European study which is ongoing. The Company is seeking additional samples to determine the variability in clinical and preclinical levels in primates infected with BSE that come down with the primate equivalent of vCJD.
Most read news
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Takara Bio and Eppendorf cooperate - Automation of Takara Bio’s Chemistries on Eppendorf’s Automated Pipetting Systems for Significantly Higher Efficiency
University of Leicester researchers discover new fluorescent silicon nanoparticles - Research may ultimately track the uptake of drugs by the body's cells
Live-cell microscopy reveals cell migration by direct forces
PET imaging with special tracer can detect and diagnose early Alzheimer's disease
Through thick and thin - Decades-old fluid question solved
Microfluidic molecular exchanger helps control therapeutic cell manufacturing
Autonomous synthesis robot uses AI to speed up chemical discovery - Impressive ingenuity
Differentiating amino acids: Foundation for direct sequencing of individual proteins developed
Research under high pressure - Why 3,000 bars are needed to take a comprehensive look at a protein
Oxford Gene Technology and Abcodia form Partnership - Companies Combine Expertise to Advance Biomarkers for the Early Diagnosis of Pancreatic Cancer